Skip to main content
. 2020 Apr 8;10:6083. doi: 10.1038/s41598-020-63180-8

Figure 5.

Figure 5

(A,B) Circulating HPV-DNA levels (copies/ml) in 16 evaluable cf-DNA samples (4A) and three evaluable EV-DNA samples (4B) of patients with locally advanced HPV-OPCSCC disease at baseline (pre- curative treatment) and at follow-up (post- curative treatment).